Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRCAAway
NCT03012321Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Jan 2017
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib and Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Northwestern University. Primary endpoint: Objective Progression Free Survival up to 2 years. Started Jan 2017; status: active, not recruiting.
02
Drugs
olaparibAbiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03012321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012321.